papaverine has been researched along with Innate Inflammatory Response in 11 studies
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism of the papaverine (PV) for the treatment of cerebral ischemia remains unclear." | 7.96 | Pluripotent anti-inflammatory immunomodulatory effects of papaverine against cerebral ischemic-reperfusion injury. ( Gu, H; Guan, S; Liu, J; Liu, Q; Qi, YF; Wang, Z; Wei, PL; Zhang, YY, 2020) |
| " Natural products have been a rich source of drug discovery, Theophylline and Methylxanthine originated from tea leaves used for asthma treatment, whereas, Papaverine, a natural isoquinolein originated from Papaver somniferum traditionally used in impotency, altogether as caffeine where firstly described as PDE-inhibiting compounds." | 4.95 | Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. ( Abusnina, A; Lugnier, C, 2017) |
| "The mechanism of the papaverine (PV) for the treatment of cerebral ischemia remains unclear." | 3.96 | Pluripotent anti-inflammatory immunomodulatory effects of papaverine against cerebral ischemic-reperfusion injury. ( Gu, H; Guan, S; Liu, J; Liu, Q; Qi, YF; Wang, Z; Wei, PL; Zhang, YY, 2020) |
| "We previously identified papaverine as an inhibitor of receptor for advanced glycation end-products (RAGE) and showed its suppressive effect on high mobility group box 1 (HMGB1)-mediated responses to inflammation." | 3.96 | Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways. ( Abe, H; Abe, T; Inoue, S; Kamiya, T; Nakajima, S; Ogawa, N; Okazawa, M; Oyama, T; Sato, A; Tachibana, H; Tamada, K; Tanuma, SI; Uchiumi, F; Yokomizo, T; Yokoue, N; Yoshimori, A; Yoshizawa, K, 2020) |
| "In rats pretreated with indomethacin, injection of PGE1 (prostaglandin E1) with carrageenan potentiated the carrageenan paw oedema." | 3.66 | Characteristics of prostaglandin E1 potentiation of inflammatory activity of some agents. ( Thomas, G, 1980) |
| "Papaverine was found to directly inhibit HMGB1/RAGE interaction." | 1.51 | Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses. ( Abe, H; Abe, T; Inada, M; Inoue, S; Nakajima, S; Ogawa, N; Oyama, T; Sato, A; Shibasaki, H; Suzuki, Y; Takasawa, R; Tamada, K; Tanuma, S; Watanabe, N; Yokomizo, T; Yoshimori, A, 2019) |
| "Papaverine and zolpidem were recently shown to be protective of bioenergetic loss in cell models of optic neuropathy." | 1.46 | Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules. ( Cortopassi, GA; Datta, S; McMackin, MZ; Yu, AK, 2017) |
| "Papaverine, which is a smooth muscle relaxant, also acted as an antagonist." | 1.29 | A possible approach to the suppression of side effects induced by PGE1. ( Kubota, M; Nakabou, Y; Ojima, M; Takada, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Ručilová, V | 1 |
| Świerczek, A | 1 |
| Vanda, D | 1 |
| Funk, P | 1 |
| Lemrová, B | 1 |
| Gawalska, A | 1 |
| Bucki, A | 1 |
| Nowak, B | 1 |
| Zadrożna, M | 1 |
| Pociecha, K | 1 |
| Soural, M | 1 |
| Wyska, E | 1 |
| Pawłowski, M | 1 |
| Chłoń-Rzepa, G | 1 |
| Zajdel, P | 1 |
| Guan, S | 1 |
| Liu, Q | 1 |
| Gu, H | 1 |
| Zhang, YY | 1 |
| Wei, PL | 1 |
| Qi, YF | 1 |
| Liu, J | 1 |
| Wang, Z | 1 |
| Nakajima, S | 2 |
| Ogawa, N | 2 |
| Yokoue, N | 1 |
| Tachibana, H | 1 |
| Tamada, K | 2 |
| Okazawa, M | 1 |
| Sato, A | 2 |
| Oyama, T | 2 |
| Abe, H | 2 |
| Kamiya, T | 1 |
| Yoshimori, A | 2 |
| Yoshizawa, K | 1 |
| Inoue, S | 2 |
| Yokomizo, T | 2 |
| Uchiumi, F | 1 |
| Abe, T | 2 |
| Tanuma, SI | 1 |
| Saglam, E | 1 |
| Zırh, S | 1 |
| Aktas, CC | 1 |
| Muftuoglu, SF | 1 |
| Bilginer, B | 1 |
| Abusnina, A | 1 |
| Lugnier, C | 1 |
| Yu, AK | 1 |
| Datta, S | 1 |
| McMackin, MZ | 1 |
| Cortopassi, GA | 1 |
| Inada, M | 1 |
| Shibasaki, H | 1 |
| Takasawa, R | 1 |
| Suzuki, Y | 1 |
| Watanabe, N | 1 |
| Tanuma, S | 1 |
| Thomas, G | 1 |
| Nakabou, Y | 1 |
| Kubota, M | 1 |
| Takada, K | 1 |
| Ojima, M | 1 |
| Tallet, D | 1 |
| Del Soldato, P | 1 |
| Oudart, N | 1 |
| Burgaud, JL | 1 |
| Grega, GJ | 1 |
| Adamski, SW | 1 |
1 review available for papaverine and Innate Inflammatory Response
| Article | Year |
|---|---|
Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Asthma; Biological Products; Cell Line, Tumor; Cell Pr | 2017 |
10 other studies available for papaverine and Innate Inflammatory Response
| Article | Year |
|---|---|
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclic Nucleotide Phosphodiesterases, Type 7 | 2021 |
Pluripotent anti-inflammatory immunomodulatory effects of papaverine against cerebral ischemic-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cytokines; Disease Models, Animal; Gene Expressio | 2020 |
Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways.
Topics: Animals; HMGB1 Protein; Inflammation; Interleukin-6; Janus Kinases; Macrophages; MAP Kinase Signalin | 2020 |
Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-
Topics: Animals; Apoptosis; Brain Injuries, Traumatic; Inflammation; Male; Mice; Neuroprotective Agents; NF- | 2021 |
Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules.
Topics: Animals; Disease Models, Animal; DNA, Mitochondrial; Electron Transport Complex I; Glaucoma, Open-An | 2017 |
Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Female; HMGB1 Protein; Inflammation; Interleukin-6; Mice; Mice, I | 2019 |
Characteristics of prostaglandin E1 potentiation of inflammatory activity of some agents.
Topics: Adenosine; Animals; Bradykinin; Carrageenan; Drug Synergism; Edema; Histamine; Indomethacin; Inflamm | 1980 |
A possible approach to the suppression of side effects induced by PGE1.
Topics: Alprostadil; Animals; Atropine; Capillary Permeability; Gabexate; Guanidines; Guinea Pigs; Histamine | 1995 |
NO-steroids: potent anti-inflammatory drugs with bronchodilating activity in vitro.
Topics: Animals; Anti-Inflammatory Agents; Bronchi; Bronchoconstrictor Agents; Bronchodilator Agents; Dexame | 2002 |
Differential effects of inhibitors of cellular function on inflammatory mediator-stimulated increases in vascular permeability.
Topics: Animals; Bradykinin; Capillary Permeability; Cricetinae; Dextrans; Fluorescein-5-isothiocyanate; His | 1991 |